Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the company made false statements regarding the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's IPO and subsequent securities purchases [1]. Group 1: Class Action Details - Investors who purchased Alto securities during the class period from February 2, 2024, to October 22, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit claims that throughout the class period, defendants made materially false and misleading statements regarding Alto's business and prospects, particularly concerning the effectiveness of ALTO-100 in treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against the Company - The complaint alleges that the product pipeline, specifically ALTO-100, was less effective in treating major depressive disorder than previously claimed, leading to overstated clinical and commercial prospects [4]. - As a result of these misleading statements, the company's business and financial outlook were also overstated, impacting the accuracy of public statements made by the company [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [6].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

Group 1 - A class action has been filed on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) [1] - The class action pertains to purchases of common stock made during Alto's initial public offering on or about February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [1] - Alto Neuroscience is identified as a clinical-stage biopharmaceutical company based in the U.S. [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about a class action lawsuit related to misleading statements made during the company's IPO and subsequent period [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Alto securities during the IPO on February 2, 2024, and up until October 22, 2024 [1]. - A lead plaintiff deadline has been set for September 19, 2025, for those wishing to represent the class [1][3]. Group 2: Compensation Information - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 3: Allegations Against Alto Neuroscience - The lawsuit claims that Alto made materially false and misleading statements regarding its product ALTO-100, particularly its effectiveness in treating major depressive disorder (MDD) [5]. - It is alleged that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to inflated business and financial prospects for Alto [5].

Accessibility StatementSkip Navigation NEW YORK, Sept. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquir ...

Core Viewpoint - A class action securities lawsuit has been filed against Alto Neuroscience, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's initial public offering and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Alto common stock related to the initial public offering on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [2]. - The complaint alleges that the defendants made false statements regarding the effectiveness of the product pipeline, ALTO-100, in treating major depressive disorder, overstating its clinical, regulatory, and commercial prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 19, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug ALTO-100 during the class period from February 2, 2024, to October 22, 2024 [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Alto securities during the specified class period [2]. - Investors have until September 19, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that key information about ALTO-100's effectiveness was not disclosed [3]. Group 2: Impact on Stock Price - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for treating Major Depressive Disorder (MDD), leading to a significant stock price drop [4]. - Following the announcement, Alto's stock price fell by $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [4]. Group 3: Contact Information - Investors who suffered losses or have questions regarding the lawsuit can contact Bragar Eagel & Squire, P.C. for more information [5][8].

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...